Regeneron Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $3,884,300 | $3,754,300 | $3,675,600 | $3,028,700 |
Gross Profit | 3,299,700 | 3,232,700 | 3,145,400 | 2,564,400 |
EBITDA | 1,200,900 | 1,919,300 | 1,657,400 | 1,040,600 |
EBIT | 1,055,900 | 1,782,600 | 1,522,300 | 913,700 |
Net Income | 844,600 | 1,460,000 | 1,391,600 | 808,700 |
Net Change In Cash | 3,884,300 | 3,754,300 | 3,675,600 | 3,028,700 |
Free Cash Flow | 922,000 | 1,417,300 | 967,600 | 773,600 |
Cash | 3,118,100 | 2,506,400 | 1,995,800 | 3,090,200 |
Basic Shares | 107,500 | 107,200 | 108,600 | 111,200 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $14,342,900 | $14,202,000 | $13,117,200 | $12,172,900 |
Gross Profit | 12,242,200 | 12,231,500 | 12,233,500 | 10,467,700 |
EBITDA | 5,818,200 | 5,318,000 | 4,047,100 | 5,259,600 |
EBIT | 5,274,500 | 4,835,100 | 4,047,100 | 4,918,200 |
Net Income | 4,504,900 | 4,412,600 | 3,953,600 | 4,338,400 |
Net Change In Cash | 14,342,900 | 14,202,000 | 13,117,200 | 12,172,900 |
Cost of Revenue | 221,300 | |||
Free Cash Flow | 4,080,500 | 3,664,600 | 3,667,600 | 4,424,800 |
Cash | 3,118,100 | 2,488,200 | 2,730,000 | 3,105,900 |
Basic Shares | 108,600 | 115,100 | 113,700 | 113,500 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | $11.44 |
2025-09-30 | $11.83 |
2025-06-30 | $12.89 |